logo.jpg
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
13 mai 2024 06h05 HE | AC Immune SA
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update Landmark deal announced with Takeda for ACI-24.060 with $100 million upfront and total potential payments for...
logo.jpg
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
13 mai 2024 06h00 HE | AC Immune SA
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease Takeda to receive exclusive option to license global rights...
logo.jpg
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
14 mars 2024 07h00 HE | AC Immune SA
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2ACI-7104.056 VacSYn Phase 2 trial in...
logo.jpg
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
22 févr. 2024 07h00 HE | AC Immune SA
AC Immune Announces Upcoming Presentations at AD/PD™ 2024 Multiple presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024)Andrea Pfeifer, Ph.D., CEO to...
logo.jpg
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
22 janv. 2024 07h00 HE | AC Immune SA
AC Immune to Regain Global Rights to Crenezumab and Semorinemab Company’s strategy is focused on advancing the Phase 2 development of its three active immunotherapiesActive immunotherapy now...
logo.jpg
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
03 janv. 2024 08h10 HE | AC Immune SA
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases ABATE Phase 1b/2 AD trial of ACI-24.060 completed enrollment of cohorts 1 and 2 and...
logo.jpg
AC Immune Announces Pricing of Underwritten Offering of Common Shares
15 déc. 2023 07h56 HE | AC Immune SA
AC Immune Announces Pricing of Underwritten Offering of Common Shares Lausanne, Switzerland, December 15, 2023 – AC Immune SA (Nasdaq: ACIU) (the “Company” or “AC Immune”), a clinical-stage...
logo.jpg
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial
15 déc. 2023 07h22 HE | AC Immune SA
AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial Potentially registration-enabling Phase 2b study (ReTain) will evaluate the effect of...
ACIU_CSO Madiha Derouazi
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
01 déc. 2023 07h00 HE | AC Immune SA
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO Outstanding scientist and entrepreneur Dr. Madiha Derouazi appointed as new CSORetiring CSO Dr....
logo.jpg
AC Immune to Present at the Jefferies 2023 London Healthcare Conference
07 nov. 2023 07h00 HE | AC Immune SA
AC Immune to Present at the Jefferies 2023 London Healthcare Conference Lausanne, Switzerland, November 7, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering...